Table of Contents
- Trial overview
- Blood disorders studied
- Who can join these studies
- Trial phases and study designs
- Main endpoints and what they measure
- Special populations and specific trial goals
- Safety and long-term follow-up
Trial overview
These studies investigate Luspatercept in people with different causes of anemia, which means low red blood cell levels.[1][2] The trials are authorised and include interventional studies, where participants receive a study treatment and researchers measure the results.[1][2]
The source data shows studies in beta-thalassemia, alpha-thalassemia, myelodysplastic syndromes, myelofibrosis, and rare inherited anemias.[1][2] Some studies compare Luspatercept with placebo or with other anemia treatments, while others are single-arm studies, meaning everyone in the study gets the same study treatment.[2][3]
Blood disorders studied
Thalassemia is studied in both adults and younger patients.[1] One trial focuses on non-transfusion dependent beta-thalassemia and asks whether treatment can improve brain oxygen use after hemoglobin rises by at least 1 g/dL.[1] Another Phase 2 study includes pediatric participants with beta-thalassemia and looks at dose selection and pharmacokinetics, which is how the body handles the study drug.[1]
Myelodysplastic syndrome (MDS) is another major area of study.[2] Several trials focus on lower-risk MDS, including people with ring sideroblasts, del5q, or no ring sideroblasts, and many of these participants either need red blood cell transfusions or do not need them.[2][3]
Myelofibrosis is also studied, including people with MPN-associated myelofibrosis who need transfusions and are on JAK2 inhibitor therapy.[2] One study also follows people who have already taken part in earlier Luspatercept trials to learn about long-term safety.[2]
One trial studies rare inherited anemias, and another focuses on alpha-thalassemia in adults and adolescents.[1][2] In that alpha-thalassemia study, adult and adolescent groups have different goals, with adults mainly assessed for erythroid response and adolescents studied for safe and tolerable dose selection.[1]
Who can join these studies
Each trial has its own entry rules, but the source data gives some clear patterns.[1][2] Some studies include only adults, such as the myelofibrosis and many MDS trials, while others include children or adolescents, such as the beta-thalassemia and alpha-thalassemia studies.[1][2]
Several MDS studies are for people who are erythropoiesis-stimulating agent (ESA) naive, which means they have not used this type of anemia treatment before.[2] Other studies include people who are refractory, intolerant, or ineligible for prior ESA treatment, meaning the earlier treatment did not work, caused problems, or could not be used.[2]
Some trials focus on people who need red blood cell transfusions, while others focus on people who do not need transfusions.[1][2] This is important because the studies are trying to see whether Luspatercept can reduce transfusion burden, improve hemoglobin, or both.[2]
Trial phases and study designs
The source data includes Phase 1, Phase 2, Phase 3, and Phase 3b studies, plus one low-intervention study.[1][2] Phase 1 studies usually help find the best dose and check early safety, while Phase 2 and Phase 3 studies test how well the treatment works and continue safety monitoring.[1][2]
One study is a randomized Phase I/II multicenter trial in lower-risk MDS without ring sideroblasts, and it has a dose-finding part and a later comparison part.[2] Another is an open-label, single-arm study, which means both researchers and participants know what treatment is given and there is no comparison group.[1]
Some Phase 3 trials compare Luspatercept with other treatments such as epoetin alfa, while others compare it with placebo in specific disease groups.[2] There is also a rollover Phase 3b study that follows people who already joined earlier Luspatercept trials so researchers can learn more about long-term safety.[2]
Main endpoints and what they measure
The main endpoint in many studies is red blood cell transfusion independence (RBC-TI), which means a person goes for a set period without needing transfusions.[2] Different trials use different time frames, such as 8 weeks, 12 weeks, or a continuous 16-week interval, so the exact definition changes from study to study.[2]
Some studies measure a rise in hemoglobin, often by at least 1.0 g/dL or 1.5 g/dL, because this shows improvement in anemia.[1][2] In the alpha-thalassemia study, adult cohorts are measured by either lower transfusion burden or a rise in hemoglobin without transfusions, while adolescent cohorts are also checked for dose-limiting toxicities, PK, and adverse events.[1]
One thalassemia study uses MRI-based measurement of cerebral metabolic rate of oxygen (CMRO2), which means how much oxygen the brain uses.[1] That study asks whether correcting anemia with Luspatercept can improve brain oxygenation in non-transfusion dependent beta-thalassemia.[1]
In the long-term safety study, the endpoints include adverse events, progression to high or very high-risk MDS, progression to acute myeloid leukemia in MDS and myelofibrosis, and development of other malignancies or premalignancies.[2] These outcomes show that the study is not only checking benefit, but also watching for disease worsening over time.[2]
Special populations and specific trial goals
Several studies are designed for very specific patient groups, which helps researchers answer focused questions.[1][2] For example, the del5q MDS study includes people with very low, low, or intermediate-risk disease who are refractory, resistant, intolerant, or ineligible to earlier treatments and who need transfusions.[2]
The lower-risk MDS study comparing Luspatercept with epoetin alfa looks at people who have not taken ESA treatment before and need transfusions.[2] Another lower-risk MDS study without ring sideroblasts looks at whether combining Luspatercept with EPO may improve response compared with Luspatercept alone.[2]
The myelofibrosis study with momelotinib and Luspatercept is testing a combination approach in transfusion-dependent disease, with the main goal of transfusion independence by Week 24.[2] This is important because it shows the research is also looking at combination treatment, not only Luspatercept alone.[2]
The rare inherited anemia study includes patient groups named in the source as CSA, CDA, and NTD-DBA, and it measures whether transfusion burden falls or hemoglobin rises over 12 weeks.[1] The source summary says this study looks for either transfusion independence, a major reduction in transfusions, or a meaningful hemoglobin increase.[1]
Safety and long-term follow-up
Safety is an important part of nearly every trial in the source data.[1][2] Some studies measure adverse events, which are unwanted medical problems that happen during the trial, and some also track serious outcomes such as disease progression or new cancers.[2]
The pediatric alpha-thalassemia study includes specific safety checks such as dose-limiting toxicities and the frequency, severity, and seriousness of adverse events.[1] This helps researchers decide whether the dose is safe and tolerable for younger participants.[1]
The rollover Phase 3b study is especially important because it follows people after earlier Luspatercept trials and looks at long-term safety across diseases such as MDS, beta-thalassemia, and myelofibrosis.[2] This kind of follow-up helps researchers understand what happens with longer use in trial participants.[2]
